Page last updated: 2024-10-20
thymine and Nausea
thymine has been researched along with Nausea in 6 studies
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 7.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage-line treatment for metastatic colorectal cancer (mCRC)." | 7.83 | Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study. ( Aoyama, T; Hama, T; Inoue, A; Kawakami, K; Machida, Y; Suenaga, M; Sugisaki, T; Sugita, K; Suzuki, K; Takiguchi, T; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2016) |
| "Evaluation demonstrated a trend toward thymidine protection of carboplatin-induced treatment-limiting thrombocytopenia." | 5.09 | Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer. ( Alberti, D; Arzoomanian, RZ; Cohen, JD; Feierabend, C; Jacobson, E; Katschinski, DM; Mehta, M; Olsen, M; Robins, HI; Tiggelaar, CL; Tutsch, K; Wilding, G, 1999) |
| "This study aimed to clarify the tolerability of a trifluridine/tipiracil combination tablet (TAS-102) in patients with advanced or recurrent colorectal cancer over 75 years of age." | 3.91 | Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2019) |
| "A novel oral agent that consists of trifluridine and tipiracil hydrochloride (TFTD) has been established as salvage-line treatment for metastatic colorectal cancer (mCRC)." | 3.83 | Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study. ( Aoyama, T; Hama, T; Inoue, A; Kawakami, K; Machida, Y; Suenaga, M; Sugisaki, T; Sugita, K; Suzuki, K; Takiguchi, T; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2016) |
| " Major adverse events were neutropenia, leukopenia, anemia, and nausea." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| " Adverse events to TAS-102 monotherapy were observed in 22 out of 23 cases (95." | 1.43 | Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer. ( Asano, H; Go, M; Ito, D; Iwai, M; Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2016) |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kimura, M | 2 |
| Usami, E | 2 |
| Teramachi, H | 2 |
| Yoshimura, T | 2 |
| Yoshino, T | 1 |
| Kojima, T | 1 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 1 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Doi, T | 1 |
| Ohtsu, A | 1 |
| Go, M | 1 |
| Iwai, M | 1 |
| Ito, D | 1 |
| Asano, H | 1 |
| Sugita, K | 1 |
| Kawakami, K | 1 |
| Yokokawa, T | 1 |
| Sugisaki, T | 1 |
| Takiguchi, T | 1 |
| Aoyama, T | 1 |
| Suzuki, K | 1 |
| Suenaga, M | 1 |
| Yamaguchi, K | 1 |
| Inoue, A | 1 |
| Machida, Y | 1 |
| Yamaguchi, T | 1 |
| Hama, T | 1 |
| Hong, DS | 1 |
| Abbruzzese, JL | 1 |
| Bogaard, K | 1 |
| Lassere, Y | 1 |
| Fukushima, M | 1 |
| Mita, A | 1 |
| Kuwata, K | 1 |
| Hoff, PM | 1 |
| Robins, HI | 1 |
| Tutsch, K | 1 |
| Katschinski, DM | 1 |
| Jacobson, E | 1 |
| Mehta, M | 1 |
| Olsen, M | 1 |
| Cohen, JD | 1 |
| Tiggelaar, CL | 1 |
| Arzoomanian, RZ | 1 |
| Alberti, D | 1 |
| Feierabend, C | 1 |
| Wilding, G | 1 |
Trials
3 trials available for thymine and Nausea
| Article | Year |
|---|---|
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cohort Studies; Drug Administration Schedule; Drug | 1999 |
Other Studies
3 other studies available for thymine and Nausea
| Article | Year |
|---|---|
Evaluation of Tolerability of Trifluridine/Tipiracil Combination Tablet in Patients With Advanced/Recurrent Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Co | 2019 |
Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Combinations; Female; | 2016 |
Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2016 |